Akums Drugs and Pharmaceuticals

Global Expansion In Europe, Brazil And India Will Unlock Opportunities

AnalystConsensusTarget

Not Invested

Consensus Narrative from 3 Analysts

Published

10 Aug 25

Updated

14 Aug 25

AnalystConsensusTarget's Fair Value

₹691.67

31.0% undervalued

14 Aug

₹477.10

-44.2%

-0.5%

-44.2%

-0.5%

Author's Valuation

₹691.7

31.0% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

₹691.7

31.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

11.44%

Life Sciences revenue growth rate

0.32%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

13.34%

Calculation

₹4.74b

Earnings '28

39.73x

PE Ratio '28

₹188.22b

Market Cap '28

₹188.22b

Market Cap '28

187.46m

No. shares '28

₹1.00k

Share Price '28

₹1.00k Share Price '28

Discounted to 2025 @ 13.32% p.a.

₹689.98

Fair Value '25